Navigation Links
US Oncology Appoints Glen Laschober EVP & Chief Operating Officer
Date:12/5/2007

HOUSTON, Dec. 5 /PRNewswire/ -- US Oncology, the nation's leading oncology services company, today named Glen Laschober as the company's new executive vice president and chief operating officer. The appointment becomes effective on January 2, 2008.

"Glen's Fortune 500 operating experience, combined with his work in large diversified healthcare organizations, greatly strengthens our existing operating team," said Bruce Broussard, president of US Oncology. "His proven success in working with physicians and healthcare professionals, in areas such as care management programs, process efficiency and leadership development, will accelerate the implementation of our company's initiatives, such as Practice and Quality Efficiency (PQE) and Comprehensive Disease Management, including Cancer Care Pathways."

"I am very pleased to join US Oncology. The company has many exciting opportunities to continue its strong growth as a leading oncology services provider," said Laschober. "Just as importantly, their mission is very compelling to me. Cancer is a devastating disease that touches the lives of a large number of people. I welcome the opportunity to help improve the quality of life for cancer patients and their families."

Laschober brings to US Oncology more than 30 years of healthcare operations experience. Most recently, he served as the chief operating officer for Omnicare, a Fortune 500 healthcare company with revenues of $6.5 billion. He has also been an executive operating officer in several other highly successful organizations such as CVS, Provantage, and Caremark. He began his healthcare career in a variety of engineering and technology operations positions working with medical devices and pharmaceutical products at G.D. Searle, Inc, currently a division of Pfizer. He graduated from the University of Illinois with a B.S. in Engineering, and from the University of Chicago with an M.B.A. in Finance.

He will be based at the company's headquarters in Houston, Texas and will report to Broussard.

About US Oncology, Inc.

US Oncology, headquartered in Houston, Texas, supports one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs and participate in many of the new cancer-related clinical research studies. US Oncology is affiliated with 1,164 physicians operating in 443 locations, including 91 radiation oncology facilities in 39 states.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
4. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. US Oncology to Report 2007 Third Quarter Earnings Results
7. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
10. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
11. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
(Date:2/5/2016)... ... 2016 , ... Colorize is a web theme package created exclusively ... using Colorize's dynamic moving camera. Colorize is perfect for personal and web related videos ... with 1 to 5 focus points per scene, stage floor scene presets that are ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... for Patients with Rare Diseases, a continuing medical education (CME) event presented by ... first of its kind—and a first for ACCORD, whose mission is to provide ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... that Medicare San Luis Obispo users can expect to see in 2016. To view ... two most significant changes will directly impact many San Luis Obispo seniors who rely ...
(Date:2/4/2016)... ... February 04, 2016 , ... American Addiction Centers (AAC) ... start of Project HoldSpace. Through the partnership, the two organizations seek to tackle ... between the ages of 13 and 18. Currently focused on Ohio schools, the ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , February 5, 2016 ... market research report "Fetal (Labor & Delivery) and Neonatal ... Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, ... MarketsandMarkets, This report studies the global market over the ... estimated at USD 6.28 Billion in 2015 and is ...
(Date:2/5/2016)... , February 4, 2016 France ... Spain , UK, and Israel ). It ... 1, 2, and 3 GD, segmented by age and sex in these ... epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing ... France , Germany , Italy ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
Breaking Medicine Technology: